Mereo BioPharma Valuation
| 0A9G Stock | 3.55 0.15 4.41% |
At this time, the firm appears to be overvalued. Mereo BioPharma Group secures a last-minute Real Value of USD3.34 per share. The latest price of the firm is USD3.55. Our model forecasts the value of Mereo BioPharma Group from analyzing the firm fundamentals such as Shares Owned By Insiders of 1.02 %, return on equity of -0.74, and Operating Margin of (38.07) % as well as examining its technical indicators and probability of bankruptcy.
Enterprise Value 2.7 B |
Overvalued
Today
Please note that Mereo BioPharma's price fluctuation is unstable at this time. Calculation of the real value of Mereo BioPharma Group is based on 3 months time horizon. Increasing Mereo BioPharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Mereo stock is determined by what a typical buyer is willing to pay for full or partial control of Mereo BioPharma Group. Since Mereo BioPharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Mereo Stock. However, Mereo BioPharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.55 | Real 3.34 | Hype 3.56 | Naive 3.69 |
The intrinsic value of Mereo BioPharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Mereo BioPharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Mereo BioPharma Group helps investors to forecast how Mereo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Mereo BioPharma more accurately as focusing exclusively on Mereo BioPharma's fundamentals will not take into account other important factors: Mereo BioPharma Total Value Analysis
Mereo BioPharma Group is presently projected to have takeover price of 2.68 B with market capitalization of 2.68 B, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Mereo BioPharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.68 B | 2.68 B |
Mereo BioPharma Investor Information
About 68.0% of the company shares are owned by institutions such as pension funds. The company recorded a loss per share of 0.28. Mereo BioPharma Group had not issued any dividends in recent years. Based on the key measurements obtained from Mereo BioPharma's financial statements, Mereo BioPharma Group is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Mereo BioPharma Asset Utilization
One of the ways to look at asset utilization of Mereo is to check how much profit was generated for every dollar of assets it reports. Mereo BioPharma Group secures a negative usage of assets of -0.31 %, losing USD0.003065 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Mereo BioPharma Group shows how discouraging it operates for each dollar spent on its assets.Mereo BioPharma Profitability Analysis
The company reported the revenue of 1000 K. Net Loss for the year was (34.2 M) with profit before overhead, payroll, taxes, and interest of 936 K.About Mereo BioPharma Valuation
The stock valuation mechanism determines Mereo BioPharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Mereo BioPharma Group based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Mereo BioPharma. We calculate exposure to Mereo BioPharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Mereo BioPharma's related companies.Additional Tools for Mereo Stock Analysis
When running Mereo BioPharma's price analysis, check to measure Mereo BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo BioPharma is operating at the current time. Most of Mereo BioPharma's value examination focuses on studying past and present price action to predict the probability of Mereo BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mereo BioPharma's price. Additionally, you may evaluate how the addition of Mereo BioPharma to your portfolios can decrease your overall portfolio volatility.